SI3329909T1 - Fenfluramin za uporabo pri zdravljenju Dravetovega sindroma - Google Patents

Fenfluramin za uporabo pri zdravljenju Dravetovega sindroma

Info

Publication number
SI3329909T1
SI3329909T1 SI201431811T SI201431811T SI3329909T1 SI 3329909 T1 SI3329909 T1 SI 3329909T1 SI 201431811 T SI201431811 T SI 201431811T SI 201431811 T SI201431811 T SI 201431811T SI 3329909 T1 SI3329909 T1 SI 3329909T1
Authority
SI
Slovenia
Prior art keywords
fenfluramine
treatment
dravet syndrome
dravet
syndrome
Prior art date
Application number
SI201431811T
Other languages
English (en)
Inventor
Berten Ceulemans
Lieven Lagae
Original Assignee
Katholieke Universiteit Leuven KU, Leuven Research & Development
University Hospital Antwerp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50729472&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3329909(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Katholieke Universiteit Leuven KU, Leuven Research & Development, University Hospital Antwerp filed Critical Katholieke Universiteit Leuven KU, Leuven Research & Development
Publication of SI3329909T1 publication Critical patent/SI3329909T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
SI201431811T 2013-05-03 2014-05-01 Fenfluramin za uporabo pri zdravljenju Dravetovega sindroma SI3329909T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/887,014 US9549909B2 (en) 2013-05-03 2013-05-03 Method for the treatment of dravet syndrome
EP18152406.7A EP3329909B1 (en) 2013-05-03 2014-05-01 Fenfluramine for use in the treatment of dravet syndrome

Publications (1)

Publication Number Publication Date
SI3329909T1 true SI3329909T1 (sl) 2021-08-31

Family

ID=50729472

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431811T SI3329909T1 (sl) 2013-05-03 2014-05-01 Fenfluramin za uporabo pri zdravljenju Dravetovega sindroma

Country Status (17)

Country Link
US (13) US9549909B2 (sl)
EP (2) EP2991637B1 (sl)
JP (3) JP6441313B2 (sl)
AU (4) AU2014261329B2 (sl)
BR (1) BR112015027282A8 (sl)
CA (1) CA2909335C (sl)
CY (1) CY1124298T1 (sl)
DK (2) DK3329909T3 (sl)
ES (2) ES2666657T3 (sl)
HR (1) HRP20210819T1 (sl)
HU (1) HUE054577T2 (sl)
LT (1) LT3329909T (sl)
NO (1) NO3092234T3 (sl)
PL (2) PL3329909T3 (sl)
PT (2) PT3329909T (sl)
SI (1) SI3329909T1 (sl)
WO (1) WO2014177676A1 (sl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
KR102245345B1 (ko) * 2014-09-29 2021-04-28 조게닉스 인터내셔널 리미티드 의약품 배포 제어를 위한 제어 시스템
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
HRP20220822T1 (hr) * 2015-02-25 2022-10-28 The Regents Of The University Of California 5ht agonisti za liječenje poremećaja epilepsije
JP6668045B2 (ja) * 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的５−ｈｔ受容体アゴニストおよびアンタゴニスト
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
KR102481631B1 (ko) * 2015-08-24 2022-12-27 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
SG11201802870RA (en) 2015-10-09 2018-05-30 Univ Southampton Modulation of gene expression and screening for deregulated protein expression
AU2016370653A1 (en) 2015-12-14 2018-06-21 Cold Spring Harbor Laboratory Antisense oligomers for treatment of Autosomal Dominant Mental Retardation-5 and Dravet Syndrome
KR102688278B1 (ko) 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
SG11201900975XA (en) 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US20180092864A1 (en) * 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
MX2019005779A (es) * 2016-11-22 2019-08-22 Ovid Therapeutics Inc Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
US10765646B2 (en) 2017-04-13 2020-09-08 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
US20200170965A1 (en) * 2017-05-09 2020-06-04 Zogenix International Limited Methods of treating doose syndrome using fenfluramine
EP4303321A3 (en) 2017-08-25 2024-07-24 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
US20190125697A1 (en) * 2017-09-26 2019-05-02 Zogenix International Limited Method of reduction in convulsive seizure frequency
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019067413A1 (en) * 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
MX2020011695A (es) 2018-05-04 2021-02-26 Stoke Therapeutics Inc Métodos y composiciones para el tratamiento de la enfermedad por almacenamiento de éster de colesterilo.
US11571397B2 (en) * 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
JP2021530481A (ja) * 2018-07-10 2021-11-11 ゾゲニクス インターナショナル リミテッド 肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン
BR112021001135A2 (pt) * 2018-07-27 2021-04-20 Xenon Pharmaceuticals Inc. compostos e composições farmacêuticas para tratar epilepsia ou transtorno convulsivo epiléptico
US20220133652A1 (en) * 2019-02-25 2022-05-05 Zogenix International Limited A formulation for improving seizure control
CN111944835B (zh) * 2019-05-14 2022-03-29 南通大学 一种突变型gabrg2转基因斑马鱼癫痫模型的构建方法及应用
CA3151422A1 (en) * 2019-08-30 2021-03-04 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
AU2020351305A1 (en) * 2019-09-17 2022-03-24 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
AU2021270720A1 (en) 2020-05-11 2022-12-08 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
JP2004538309A (ja) 2001-07-31 2004-12-24 ワイエス 不快な味覚をマスキングするためのスクラロース調合物
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
WO2006125774A1 (en) 2005-05-25 2006-11-30 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
US9125900B2 (en) 2005-09-14 2015-09-08 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
MX2009002180A (es) 2006-08-31 2009-06-05 Univ Alberta Metodo de inhibicion de la depresion respiratoria mediante el uso de moduladores alostericos positivos del receptor ampa.
EP2254577A1 (en) 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2010040652A1 (en) 2008-10-09 2010-04-15 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Liquid pharmaceutical formulation containing paracetamol
CA2758774C (en) 2009-04-15 2015-02-03 Research Triangle Institute Monoamine reuptake inhibitors
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
AR079862A1 (es) 2010-01-08 2012-02-22 Eurand Inc Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
CN103108651A (zh) 2010-07-30 2013-05-15 默沙东公司 Cyp3a药物代谢的抑制
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
US20140030343A1 (en) 2010-10-26 2014-01-30 Alpharma Pharmaceuticals Llc Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
WO2014078575A2 (en) 2012-11-15 2014-05-22 Galleon Pharmaceuticals, Inc. Novel orally bioavailable breathing control modulating compounds, and methods of using same
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
PT3035926T (pt) 2013-08-19 2020-09-01 Univ California Compostos e métodos para tratar um distúrbio epiléptico
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
HRP20220822T1 (hr) 2015-02-25 2022-10-28 The Regents Of The University Of California 5ht agonisti za liječenje poremećaja epilepsije
NO346258B1 (en) 2015-06-30 2022-05-16 Neurad Ltd Novel breathing control modulating compounds, and methods of making and using same
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
KR102481631B1 (ko) 2015-08-24 2022-12-27 조게닉스 인터내셔널 리미티드 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
KR102688278B1 (ko) 2015-12-22 2024-07-26 조게닉스 인터내셔널 리미티드 펜플루라민 조성물 및 그 제조 방법
SG11201900975XA (en) 2016-08-24 2019-03-28 Zogenix International Ltd Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
US20200170965A1 (en) 2017-05-09 2020-06-04 Zogenix International Limited Methods of treating doose syndrome using fenfluramine

Also Published As

Publication number Publication date
US10478442B2 (en) 2019-11-19
US9603814B2 (en) 2017-03-28
BR112015027282A8 (pt) 2019-12-24
LT3329909T (lt) 2021-07-12
JP6655156B2 (ja) 2020-02-26
DK2991637T3 (en) 2018-05-07
US20140343162A1 (en) 2014-11-20
US20210121479A1 (en) 2021-04-29
PL2991637T3 (pl) 2018-07-31
HRP20210819T1 (hr) 2021-08-20
AU2014261329B2 (en) 2019-02-21
JP6966584B2 (ja) 2021-11-17
EP3329909B1 (en) 2021-03-17
AU2019203448A1 (en) 2019-06-06
US9549909B2 (en) 2017-01-24
WO2014177676A1 (en) 2014-11-06
AU2019203448B2 (en) 2020-08-06
DK3329909T3 (da) 2021-04-19
AU2014261329A1 (en) 2015-11-05
US20170151214A1 (en) 2017-06-01
JP2016518387A (ja) 2016-06-23
BR112015027282A2 (pt) 2017-07-25
CY1124298T1 (el) 2022-07-22
US20160136114A1 (en) 2016-05-19
NO3092234T3 (sl) 2018-07-14
ES2863929T3 (es) 2021-10-13
PT3329909T (pt) 2021-05-14
AU2020267264A1 (en) 2020-12-17
US20170151259A1 (en) 2017-06-01
US20140343161A1 (en) 2014-11-20
JP6441313B2 (ja) 2018-12-19
CA2909335A1 (en) 2014-11-06
US10478441B2 (en) 2019-11-19
PT2991637T (pt) 2018-04-24
US20140343044A1 (en) 2014-11-20
EP3329909A1 (en) 2018-06-06
JP2019048862A (ja) 2019-03-28
PL3329909T3 (pl) 2021-10-11
US9603815B2 (en) 2017-03-28
US9610260B2 (en) 2017-04-04
HUE054577T2 (hu) 2021-09-28
JP2020063309A (ja) 2020-04-23
US20170151257A1 (en) 2017-06-01
CA2909335C (en) 2021-05-18
ES2666657T3 (es) 2018-05-07
US20200030341A1 (en) 2020-01-30
US20220160727A1 (en) 2022-05-26
US20140329908A1 (en) 2014-11-06
EP2991637B1 (en) 2018-03-07
AU2019203832B2 (en) 2020-10-15
EP2991637A1 (en) 2016-03-09
US20170151213A1 (en) 2017-06-01
US20170151194A1 (en) 2017-06-01
AU2019203832A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
SI3329909T1 (sl) Fenfluramin za uporabo pri zdravljenju Dravetovega sindroma
IL273815B (en) Secondary vaccine particles for the treatment of inflammation
EP2950884A4 (en) COMPOSITIONS AND METHOD FOR TREATING SURFACES
GB2516335B (en) The use of phytocannabinoids in the treatment of ovarian carcinoma
SG11201600275PA (en) Novel adsorbent composition and use thereof
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
EP3015480A4 (en) Surface treatment agent
HK1215164A1 (zh) 處理方法
GB201304872D0 (en) Treatment
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
HUE046608T2 (hu) Növényalapú kompozíció köhögés kezelésében történõ alkalmazásra
EP2945946A4 (en) PROCESS FOR PREPARING AND CLEANING APIXABAN
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
SG11201507403TA (en) Adsorbing/desorbing agent
IS2934B (is) Mólýbden efnasambönd til notkunar við meðferð á sýaníðeitrun
HK1209033A1 (zh) 奧地帕西在治療黏多醣症病中的應用
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
ZA201408732B (en) Composition and methods for treating wounds
EP3104863C0 (en) SALICYLATE FOR USE IN THE TREATMENT OF CANCER
GB201304675D0 (en) Novel compositions having use in therapy
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis
AU2013901985A0 (en) Chemically Treated Structure